Hereditary hemorrhagic telangiectasia (HHT) can be fatal. However, it does not affect the average life expectancy of most people. Complications can occur when blood vessels rupture in vital organs.
A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...
A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...
In the April 2010 supplement to this journal, a series of articles prepared by the Center for Public Genomics at Duke University analyzed how patenting and licensing affect access to clinical genetic ...
Most people with this condition live a full, typical life, but it can be life threatening if a blood vessel ruptures in an internal organ and bleeds uncontrollably. Osler-Weber-Rendu syndrome, which ...
Medical imaging, like MRI, CT, and ultrasound, plays a vital role in diagnosing HHT, formerly known as Osler-Weber-Rendu syndrome. Imaging can help guide treatment and improve your outlook with HHT.
A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results